Cases & Deals

Onxeo completes €15 million private placement of new shares

Clients Onxeo

Jones Day advised Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology and listed on the regulated markets of Euronext in Paris and Nasdaq OMX in Copenhagen, in connection with its €15 million (US$16.7 million) private placement of new shares to U.S. and European investors.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.